Take advantage of Waxart’s sharp pullback, analyst says


Recent news of an adverse reaction by a participant in a clinical trial of AstraZeneca’s Kovid-19 vaccine candidate demonstrates that getting an approved vaccine to market is not straight forward. The unfortunate incident that shows up is that the race to be the first to the finish line with a viable solution is over.

The field is still open, then, for vaccine specialist Waxart (VXRT) To make its mark. Small Cap still lags far behind other key players in the development of its COVID-19 vaccine program, but after the publication of promising pre-clinical trial data, analyst B Riley FBR Mayank Mamtani has yet to stop writing to investors Call for

“We believe that VXRT stands in the midst of the second wave of C-19 vaccine manufacturers, characterized by a platform largely capable of generating humor, mucus and cellular immunity in the context of offering a convenient oral dose, and to investors. Recommend additional profit. Recent equity pullback … “

Mamatani’s latest support comes after it was developed by all four vaccine candidates that were evaluated in a mouse model from VXRT’s proprietary VAAST platform and elicited a strong immune response. The most powerful of which, rAdS-N, is most likely for Phase 1 testing, expected to begin soon. Additionally, vaccines only caused low levels of IL-4 production, preventing the risk of vaccine-dependent disease progression.

After a barely credible run up, which saw a 4900% rise in VXRT shares since the end of the year, the game has seen a sharp reversal over the past few months, as the stock retreated 73% from its year-high. is. Mamatani, however, expects the shares to beat previous milestones and has a $ 22 price target in mind, which means 360% above current levels. (To see Mamatani’s track record, Click here)

Only one other analyst has recently published a Waxart review, which is also recommending investors to buy shares. Overall, the stock has a Moderate Buy consensus rating with a $ 19.5 average price target. The benefits of 308% can be in the card, should this figure be found in the coming months. (See Waxart Stock Analysis on TipRank)

To find good ideas for healthcare stock trading at attractive valuations, TipRank’s Best Stocks to Buy, a newly launched tool that unites all TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are purely selective analysts. Content is to be used for informational purposes only. It is very important to do your own analysis before making any investment.